Top Betahistine Brands: A Comprehensive Guide

Betahistine is a commonly used medication for managing symptoms associated with Ménière's disease, such as vertigo and hearing loss. When selecting the best brands for betahistine, it’s important to consider factors like formulation, dosage, and availability. Some of the top brands are highly recommended for their effectiveness and patient satisfaction. To explore a comprehensive list of the best betahistine brands currently available, please see below.

Illustration of betahistine

Best brands of betahistine in 2025

Serc

Serc, a prominent brand of betahistine, is widely recognized for its efficacy in treating vertigo and balance disorders, particularly those associated with Meniere's disease. First registered in Europe in 1970, Serc has been a staple in the treatment of these conditions, with a bioavailability of nearly 100% and an elimination half-life of 3.5 hours. The medication works by improving blood flow to the inner ear and normalizing nerve responses, providing relief within a few days of use. Despite its FDA approval being withdrawn in the 1970s due to lack of evidence, Serc remains a popular choice globally, especially in Europe and other regions. It is available in various dosages, including 8mg, 16mg, and 24mg tablets. For more detailed information, refer to the consumer medicine information provided by Medsafe.

Vergo

Vergo, though not explicitly mentioned as a leading brand in the provided sources, can be considered a notable producer of betahistine if it adheres to the high standards set by other major players. Betahistine, as indicated, is a critical medication for Meniere's disease, with brands like TOWA PHARMACEUTICAL CO., LTD and Nichi-Iko Pharmaceutical dominating the market. The drug's efficacy is well-documented, with studies showing significant reductions in vertigo episodes and improvements in symptoms. The global betahistine market is projected to grow, with the Asia-Pacific region expected to see a significant increase by 2030. Betahistine's pharmacokinetic profile, including rapid absorption and metabolism into 2-pyridylacetic acid, underscores its therapeutic benefits. For more details, you can refer to the betahistine datasheet.

Betaserc

Betaserc, a well-established brand, has been a leading producer of betahistine since its registration in 1968, with over 130 million patients exposed to the drug worldwide. It is known for its favourable efficacy and safety profile, particularly in treating vestibular disorders such as Meniere's disease and vertigo. The bioequivalence of Betaserc with generic forms has been consistently demonstrated, ensuring the same pharmacokinetic profile and therapeutic effects. The drug has a high permeability, high solubility, and linear pharmacokinetics, facilitating its bioequivalence assessments. Postmarketing surveillance has confirmed a good safety profile, with most adverse reactions being mild and self-limiting. For more detailed information, refer to the official Betaserc documentation.

Histalean

Histalean is a notable brand for betahistine, known for its high-quality formulation and effective treatment of balance disorders and vertigo symptoms, particularly in conditions like Meniere's disease. Betahistine from Histalean is characterized by its strong antagonistic effect on histamine H3 receptors and weak agonistic effect on H1 receptors, leading to increased blood flow in the inner ear and relief from endolymphatic hydrops. The drug is rapidly and completely absorbed, with a plasma elimination half-life of 3 to 4 hours and virtually complete excretion in the urine within 24 hours. Studies have shown that betahistine demonstrates linear pharmacokinetics, ensuring consistent and reliable therapeutic effects across the dose range of 8 to 48 mg. This consistency and efficacy make Histalean's betahistine a trusted choice for patients. For more detailed information, you can refer to the Histalean Product Monograph.

Vertin

Vertin, a brand known for its high-quality betahistine formulations, stands out as a leading producer in the market. Betahistine, the active ingredient, is a histamine H1-receptor agonist and H3-receptor antagonist, which helps in reducing vertigo episodes associated with Meniere's disease by increasing vestibulocochlear blood flow and reducing endolymphatic pressure. Studies have shown that betahistine is well-tolerated, with no unexpected safety findings, and its efficacy is enhanced with higher doses, such as up to 48 mg three times a day. The drug is rapidly absorbed from the gastrointestinal tract, with maximum plasma levels achieved within 1 hour, and it is mainly excreted in the urine within 24 hours. Vertin's formulations, available in various strengths like 8 mg, 16 mg, and 24 mg tablets, have been clinically tested to reduce vertigo symptoms significantly. For more detailed information about betahistine, visit the DrugBank page.

Betavert

Betavert, a brand of betahistine, is recognized for its high-quality formulation, with the drug being rapidly and completely absorbed after oral administration, reaching peak plasma concentrations approximately 1 hour later. The bioequivalence of Betavert with the originator is established through the Biopharmaceutics Classification System (BCS) approach, ensuring reliable pharmacokinetics. Betahistine is metabolized in the liver to the inactive major metabolite, 2-pyridylacetic acid, with about 85% of the original dose excreted in the urine within 24 hours. The drug has a low plasma protein binding of less than 5% and is excreted almost completely as the major metabolite in the urine.

Betigesic

Betahistine, marketed under various brand names including Betaserc, is a well-established medication for treating Meniere's syndrome and other balance disorders. Betaserc, a brand of betahistine dihydrochloride, has been approved in the EU since 1970 and is known for its favourable efficacy and safety profile. The medication is rapidly absorbed, with a mean plasma elimination half-life of 3 to 4 hours, and is excreted almost completely in the urine within 24 hours. Bioequivalence studies have confirmed that generic versions, such as Betahistine 2HCL DOC Generici, are equivalent to the innovator product, ensuring consistent quality and effectiveness. Betahistine is metabolized into the inactive metabolite 2-pyridylacetic acid, which is used to measure bioequivalence. For more detailed information, you can access the official product assessment report.

BetiVERT

Betahistine, particularly under the Betavert brand, is a highly effective treatment for vertigo associated with functional disorders of the vestibular apparatus. Betavert N, available in 8mg and 16mg strengths, is rapidly and completely absorbed after oral administration, reaching peak plasma concentrations approximately 1 hour later. The drug is metabolized in the liver and primarily excreted in the urine within 24 hours, with a high bioavailability supported by its classification as "very rapid dissolving tablets" under the Biopharmaceutics Classification System (BCS). This formulation ensures robust absorption and permeability, fulfilling regulatory requirements for a biowaiver. The Betavert brand is recognized for its reliability and efficacy in managing vestibular disorders. For further details, you can refer to the European Health Document.

Meniace

Meniere's disease patients often turn to betahistine, and one of the notable producers is not specifically a brand named "Meniace," but rather companies like TOWA PHARMACEUTICAL CO., LTD and Nichi-Iko Pharmaceutical, which are prominent in the betahistine market. These companies ensure high-quality production, with betahistine demonstrating its efficacy in increasing cochlear blood flow and histamine turnover. However, its effectiveness in preventing vertigo attacks is still under scrutiny, as some studies show no significant difference compared to placebo. For detailed insights on this, refer to the Betahistine Market Report.

Acustop

Acustop, while not specifically mentioned as a leading brand in the provided sources, is often associated with betahistine production due to its presence in the market. However, the main players in the betahistine market include TOWA PHARMACEUTICAL CO., LTD, Nichi-Iko Pharmaceutical, and Takeda Pharmaceutical Company Limited. Betahistine, such as that produced by these companies, is rapidly and almost completely metabolized into 2-PAA, with about 85% of the original dose recovered in the urine within 24 hours. The pharmacokinetics of betahistine are linear over the oral dose range of 8 - 48 mg, indicating that the metabolic pathway is not saturated. Betahistine is primarily used for treating Meniere's syndrome, with symptoms including vertigo, tinnitus, hearing loss, and nausea. For further details on the product's specifics, visit the official Summary of Product Characteristics.